Inhibition of MEIS3 Generates Cetuximab Resistance through c-Met and Akt

Figure 4

(a) The IC50 pattern of LOVO-CON, LOVO MEIS3 shRNA, SNU-61 CON, and SNU-61 MEIS3. (b) The LOVO-CON, LOVO MEIS3 shRNA, SNU-61 CON, and SNU-61 MEIS3 cells were treated with different concentrations of crizotinib, and the proliferation of cells was detected using an MTT assay. (c) The LOVO cells were treated with different concentrations of crizotinib, and the expression of MEIS3, p-c-Met, and c-Met was determined by western blot (). (d) The LOVO-CON, LOVO MEIS3 shRNA, SNU-61 CON, and SNU-61 MEIS3 cells were treated with different concentrations of miltefosine, and cell proliferation was determined using an MTT assay. (e) The LOVO cells were treated with different concentrations of miltefosine, and the expression of MEIS3, p-Akt, and Akt at the protein level was determined by western blot (). (f) LOVO-CON and LOVO MEIS3 shRNA cells were treated with different concentrations of crizotinib and miltefosine, and expression of MEIS3, p-Akt, and Akt at the protein level was determined by western blot ().

(a)

(b)

(c)

(d)

(e)

(f)